Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Maciej Banach, Stanisław Surma, Željko Reiner, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Menopause and women’s cardiovascular health: is it really an obvious relationship?
Kamila Ryczkowska, Weronika Adach, Kamil Janikowski, et al.
Archives of Medical Science (2022) Vol. 19, Iss. 2, pp. 458-466
Open Access | Times Cited: 75
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Peter E. Penson, Michel Farnier, et al.
Progress in Cardiovascular Diseases (2023) Vol. 79, pp. 2-11
Open Access | Times Cited: 50
Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China
Liang Chen, Shi Chen, Xueke Bai, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2422558-e2422558
Open Access | Times Cited: 19
Ultrasound-assisted extraction, purification, sulfation of Perilla leaves polysaccharide and hypoglycemic and hypolipidemic activities
Jing Guan, Peng Guo, Meng Chen, et al.
Ultrasonics Sonochemistry (2025), pp. 107269-107269
Open Access | Times Cited: 2
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108507-108507
Open Access | Times Cited: 34
Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
Jelena Vekić, Kristine Stromsnes, Stefania Mazzalai, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2897-2897
Open Access | Times Cited: 34
2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Maciej Banach, Stanisław Surma, Peter P. Tóth
Archives of Medical Science (2023)
Open Access | Times Cited: 31
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Toshiyuki Nishikido
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, et al.
American Heart Journal (2024) Vol. 274, pp. 32-45
Open Access | Times Cited: 15
The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7
Wujun Chen, Xiaolin Wu, Jianxia Hu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Maturity-onset diabetes of the young (MODY) - in search of ideal diagnostic criteria and precise treatment
Ksenija Zečević, Špela Volčanšek, Niki Katsiki, et al.
Progress in Cardiovascular Diseases (2024) Vol. 85, pp. 14-25
Closed Access | Times Cited: 9
2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.
Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz, et al.
Archives of Medical Science (2024)
Open Access | Times Cited: 9
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Željko Reiner, Stanisław Surma, et al.
Drugs (2024)
Open Access | Times Cited: 9
Geospatial analysis and determinant factors of comorbidity presence in patients with diabetes in Peru
Víctor Juan Vera-Ponce, Fiorella E. Zuzunaga-Montoya, Luisa Erika Milagros Vásquez-Romero, et al.
Endocrine and Metabolic Science (2025), pp. 100222-100222
Open Access | Times Cited: 1
Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
Bożena Sosnowska, Weronika Adach, Stanisław Surma, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 168-168
Open Access | Times Cited: 31
A Look to the Past - What Has Had the Biggest Impact on Lipids in the Last Four Decades? A Personal Perspective
Maciej Banach, Stanisław Surma
Archives of Medical Science (2023)
Open Access | Times Cited: 17
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
Niki Katsiki, Theodosios D. Filippatos, Charalambos Vlachopoulos, et al.
Atherosclerosis Plus (2024) Vol. 55, pp. 74-92
Open Access | Times Cited: 8
Diabetic Cardiomyopathy—From Basics through Diagnosis to Treatment
Ewa Radzioch, Bartłomiej Dąbek, Marta Balcerczyk-Lis, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 765-765
Open Access | Times Cited: 8
Low‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry
Julia Brandts, Sascha R. Tittel, Peter Bramlage, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 12, pp. 3700-3708
Open Access | Times Cited: 14
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Sophie Béliard, Florian Mourre, René Valéro
Diabetologia (2024) Vol. 67, Iss. 6, pp. 974-984
Open Access | Times Cited: 5
Association between low-density lipoprotein cholesterol and sudden cardiac arrest in people with diabetes mellitus
Yun Gi Kim, Joo Hee Jeong, Kyungdo Han, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Investigating the relationship between vitamin-D deficiency and glycemia status and lipid profile in nondiabetics and prediabetics in Saudi population
Tarek Atia, Mohammad Hassan Abdelzaher, Somaia A. Nassar, et al.
Medicine (2023) Vol. 102, Iss. 47, pp. e36322-e36322
Open Access | Times Cited: 11
Assessing the impact of magnesium-based nutritional education on lipid profiles in individuals with type 2 diabetes mellitus: a quasi-experimental study
Eram Albajri, Arwa S. Almasaudi, Hala H. Mosli, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway
Fengyuan Lu, En Li, Yifeng Gao, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Page 1 - Next Page

Scroll to top